Qinghui Lianuo Biotech Secures Nearly RMB 200 Million in Series A Funding to Advance γδ T-cell Immunotherapies
Unicet Biotech
Developer of γδ T Cell Therapeutics
Recently, Beijing Qinghui Liannuo Biotechnology Co., Ltd. (hereinafter referred to as “Qinghui Liannuo” or the “Company”) announced the completion of its Series A financing round, raising nearly RMB 200 million. The investment was jointly participated in by Longpan Investment, Zhongguancun Capital, Beijing Medical and Health Industry Investment Fund, Feitu Hongyuan, and Shenzhen Capital Group. The proceeds from this financing will primarily be used for clinical studies of the company’s core pipeline, proof-of-concept for early-stage innovative pipelines, and optimization of its technology platform.
As an innovative biopharmaceutical company focused on the development of γδ T cell immunotherapy, Qinghui Liannuo has advanced multiple γδ T cell product candidates into clinical trials, leveraging its proprietary technology platform. These products have demonstrated promising therapeutic potential in the treatment of cancer and autoimmune diseases.
The company’s independently developed QH104A, the world’s first “off-the-shelf” CAR-γδ T cell injection targeting B7-H3, has attracted significant attention. Last year, in a Phase I clinical study led by Professor Li Wenbin’s team at Beijing Tiantan Hospital, Capital Medical University, the product successfully administered its first dose to a patient with recurrent or progressive malignant central nervous system tumors. Unlike traditional autologous CAR-T therapies, which require several weeks for individualized preparation, QH104A utilizes cells from healthy donors, enabling large-scale production and cryopreservation in advance. For clinical use, patients do not need to endure lengthy waiting periods; the product can be rapidly thawed and administered after quality re-verification. This “off-the-shelf” design effectively avoids treatment delays caused by prolonged manufacturing cycles for patients with rapidly progressing recurrent malignant brain tumors who have extremely narrow therapeutic windows, thereby enhancing the timeliness and accessibility of treatment.
Furthermore, QH104A leverages Qinghui Liannuo’s independently developed fully enclosed semi-automated production process system to achieve large-scale manufacturing of cell-based therapies, significantly reducing the per-dose production cost.
In addition to malignant tumors of the central nervous system, Qinghui Liannuo’s off-the-shelf γδ T-cell therapies targeting B-cell malignancies and autoimmune diseases have also demonstrated promising therapeutic potential and a manageable safety profile in investigator-initiated clinical studies. Leveraging the unique immune recognition mechanism of the γδ TCR/BTN axis, the company has deployed innovative products with novel mechanisms of action across multiple hematologic and solid tumor indications where existing CAR-T therapies have shown suboptimal efficacy or faced significant challenges, thereby continuously enriching its pipeline portfolio.
The completion of this funding round provides financial support for Qinghui Liannuo’s next phase of R&D and clinical advancement. The company stated that it will continue to focus on the innovative field of γδ T cells, steadily advance the clinical translation and registration studies of its core pipeline, and promote domestically developed innovative cell therapies to benefit more patients.
E.N.D
Declaration:ReferenceInternalRongComeSourced from Official Media/Online News, this publicOfficial AccountAimed atKnowledge sharing: We maintain neutrality regarding the content, statements, and opinions in reposted or shared materials. The related content is provided for readers' reference only.